Article

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

2025-06-27

Abstract excerpt

High-grade serous ovarian cancer demonstrates limited responsiveness to immune checkpoint inhibitors, owing in part to immunosuppressive environments shaped by nearly universal p53 aberrations. Utilizing an immunocompetent mouse model and individual p53 mutations, we identified a dependence of the p53-R270H mutation (equivalent of human R273H) on regulatory T cells (Tregs) and the PD-1/PD-L1 axis. Analysis of pati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7650d17a-d280-57d2-ab2d-820b24b1babb
DOI: 10.1101/2025.06.23.661120

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored ImmunotherapyDOI 10.1101/2025.06.23.661120Read

Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer.Semantic proximity Read

New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer.Semantic proximity Read

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Semantic proximity Read

Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.Semantic proximity Read

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.Semantic proximity Read

Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.Semantic proximity Read

PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancerSemantic proximity Read

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancerSemantic proximity Read

Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.Semantic proximity Read

Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian CancerSemantic proximity Read

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancerSemantic proximity Read

Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid HormonesSemantic proximity Read